Kelly Mary D, Vu Timothy Q, Iyer Atiriya U, Luo Yiming, Linderman Aiden P, Cline Lariana, Sanchez Crystal, Kamat Neha P
bioRxiv. 2025 Sep 9:2025.09.04.674323. doi: 10.1101/2025.09.04.674323.
Lipid nanoparticles (LNPs) are a powerful emerging tool for T cell engineering with applications ranging from B cell lymphomas to other cancers and autoimmune diseases. Key challenges in designing these therapeutics include achieving both precise cell targeting and efficient mRNA translation. While single-targeted LNPs have been extensively studied, bispecific LNPs have only been briefly explored. Engagement of multiple T cell receptors offers the opportunity for enhanced mRNA delivery, expression, and T cell targeting. Here, a DNA-tethering method enables rapid modification of lipid nanoparticles with commercial antibodies. Using this strategy, we evaluated a variety of bispecific LNPs for targeted mRNA delivery to T cells both and . We identify bispecific formulations that improve targeting and subsequent transfection of T cells and relative to monotargeted LNPs. Additionally, we find that targeting molecules can alter LNP biodistribution to the spleen and liver. This fast and efficient approach to assembling antibody-targeted LNPs should enable high-throughput screening of diverse antibody combinations for improved specificity and efficiency of gene delivery.
A major challenge in gene delivery is achieving both precise targeting and efficient mRNA translation. Multitargeted LNPs offer a potential solution to this challenge; however, their rapid assembly remains difficult, necessitating the development of new methods to construct and evaluate targeted LNPs. Here, we use a DNA-tethering method to enable rapid antibody modification of LNPs and evaluate bispecific formulations for targeted T cell mRNA delivery and . We find bispecific LNPs improve T cell targeting and expression compared to single-targeted particles. To the best of our knowledge, this study represents the first systematic screening and comparison of bispecific LNPs. Our method provides a modular approach for identifying effective antibody combinations to enhance gene delivery that can be customized for different undruggable diseases.
脂质纳米颗粒(LNPs)是一种强大的新兴T细胞工程工具,其应用范围涵盖从B细胞淋巴瘤到其他癌症以及自身免疫性疾病。设计这些疗法的关键挑战包括实现精确的细胞靶向和高效的mRNA翻译。虽然单靶向LNPs已得到广泛研究,但双特异性LNPs仅得到了初步探索。多个T细胞受体的结合为增强mRNA递送、表达和T细胞靶向提供了机会。在此,一种DNA连接方法能够用商业抗体快速修饰脂质纳米颗粒。使用该策略,我们评估了多种双特异性LNPs用于将mRNA靶向递送至T细胞。我们鉴定出相对于单靶向LNPs能改善T细胞靶向和后续转染的双特异性制剂。此外,我们发现靶向分子可改变LNP在脾脏和肝脏中的生物分布。这种快速且高效的组装抗体靶向LNPs的方法应能实现对多种抗体组合的高通量筛选,以提高基因递送的特异性和效率。
基因递送中的一个主要挑战是实现精确靶向和高效的mRNA翻译。多靶向LNPs为这一挑战提供了潜在的解决方案;然而,它们的快速组装仍然困难,需要开发新的方法来构建和评估靶向LNPs。在此,我们使用一种DNA连接方法实现对LNPs的快速抗体修饰,并评估双特异性制剂用于将mRNA靶向递送至T细胞。我们发现与单靶向颗粒相比,双特异性LNPs改善了T细胞靶向和表达。据我们所知,本研究代表了对双特异性LNPs的首次系统筛选和比较。我们的方法提供了一种模块化方法,用于识别有效的抗体组合以增强基因递送,可针对不同的不可成药疾病进行定制。